CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Cardova, Tennessee

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • Increasing HIV/STI Home Testing Via a Digital Intervention Among Black Women

    In Travis County, Texas, deemed a HIV geographic hotspot due to high HIV rates, Black women are 18.4 times more likely to contract HIV compared to women of other races/ethnicities. Black women also have higher rates of sexually transmitted infections (STIs) than other women; many STIs have no symptoms, are undiagnosed, and are untreated. Having an STI triples one's risk for contracting HIV. In Travis County, over 20% of women learned one year after contracting HIV that the the individual is HIV-positive, highlighting barriers to testing. Home HIV/STI testing has promise to increase rates of testing by circumventing barriers and thereby reduce medical costs through early detection and care. Home HIV/STI testing is also a prime opportunity to link Black women at high risk for HIV to pre-exposure prophylaxis (PrEP). Yet, home testing alone may not overcome all barriers. Pairing home testing with an intervention designed to increase motivation and overcome barriers has the most promise to increase HIV/STI testing rates. The proposed project draws on 3 components, the situated, information-motivation-behavioral (sIMB) model, mental contrasting, and implementation intentions to develop a new, web-based intervention. This intervention is comprised of 5 sessions: 1) using the HIV/STI home testing kit, 2) mailing in the kit, 3) checking results, 4) obtaining treatment, and 5) attending an appointment for PrEP. Each session is structured the same: information regarding the importance of each behavior (i.e., taking the home test, mailing in the test, checking results, linkage to care, and linkage to PrEP), motivation via mental contrasting (identifying positive outcomes and barriers to each session) and methods to overcome the identified barriers (implementation intentions), and behavioral skills to increase self-efficacy. The project will occur in 3 phases that coincide with the aims to develop and culturally tailor the intervention. 1) Conduct formative research to develop the intervention. Four focus groups (n=4-6), with 24 Black women from Travis County will explore the constructs of sIMB, mental contrasting, and implementation intentions to develop the intervention protocol to be field tested in Aim 2. 2) Field test the intervention. The investigators will test the preliminary feasibility and acceptability of the intervention with 6 participants to make any necessary adjustments for Aim 3. 3) Conduct a feasibility pilot of the intervention. The investigators will determine the feasibility, acceptability, and preliminary efficacy among 60 Black women in Travis County. Participants will be randomly assigned to the intervention or a web-based educational control. The investigators hypothesize that the intervention will be feasible, acceptable, and demonstrate a trend toward efficacy for completion of home testing, linkage to care, and linkage to PrEP. Follow-up web-based assessments will be administered 2-, 4-, and 6-months after baseline. The web-based design of the intervention greatly increases the opportunity for implementation on a large scale. The long-term goal is to increase HIV/STI testing among low-income Black women via scalable and sustainable methods to decrease HIV transmission and subsequent disparities.

    Phase

    N/A

    Span

    191 weeks

    Sponsor

    Johns Hopkins Bloomberg School of Public Health

    San Antonio, Texas

    Recruiting

    Healthy Volunteers

  • A Varegacestat Hepatic Impairment Study

    This is an open-label, single-dose, parallel study to evaluate the effects of varying degrees of impaired hepatic function on the PK, safety, and tolerability of varegacestat in adult participants. The study will be conducted sequentially. The study will enroll participants with mild (Group 2) and moderate (Group 3) hepatic impairment (HI) and healthy participants with normal hepatic function (Group 1) at a 1:1 ratio. Matched healthy participants may match to more than one participant in the HI groups. Subsequently, if appropriate, the study will enroll participants with severe (Group 4) HI and healthy participants with normal hepatic function (Group 1), as needed, to provide 1:1 matches for Group 4. The decision to conduct Group 4 enrollment will be contingent upon the assessment of the feasibility, PK, and safety data from Groups 1-3.

    Phase

    1

    Span

    43 weeks

    Sponsor

    Immunome, Inc.

    San Antonio, Texas

    Recruiting

    Healthy Volunteers

  • A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

    Phase

    1

    Span

    61 weeks

    Sponsor

    X4 Pharmaceuticals

    San Antonio, Texas

    Recruiting

    Healthy Volunteers

  • Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

    Phase

    1

    Span

    61 weeks

    Sponsor

    Celgene

    San Antonio, Texas

    Recruiting

    Healthy Volunteers

  • A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants

    Phase

    1

    Span

    39 weeks

    Sponsor

    Eli Lilly and Company

    San Antonio, Texas

    Recruiting

    Healthy Volunteers

  • A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo

    Phase

    1

    Span

    100 weeks

    Sponsor

    Dren Bio

    San Antonio, Texas

    Recruiting

  • A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment

    Phase

    1

    Span

    65 weeks

    Sponsor

    Bristol-Myers Squibb

    San Antonio, Texas

    Recruiting

    Healthy Volunteers

  • A Study of RSLV-132 in Females With Sjögren's Syndrome

    Phase

    2

    Span

    96 weeks

    Sponsor

    Resolve Therapeutics

    San Antonio, Texas

    Recruiting

  • A Research Study on Etavopivat in Participants With and Without Liver Disease

    Phase

    1

    Span

    66 weeks

    Sponsor

    Novo Nordisk A/S

    San Antonio, Texas

    Recruiting

  • A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease

    Phase

    2

    Span

    145 weeks

    Sponsor

    Tourmaline Bio, Inc.

    San Antonio, Texas

    Recruiting

1-10 of 127
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 609.945.0101

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information